Discovery of Substituted 1,2,3-Triazolyl-Benzoylacetamides as Potent MMP-9 Inhibitors with Anti-Angiogenic Activity in MDA-MB-231 TripleNegative Breast Cancer
Matrix metalloproteinase-9 (MMP-9) contributes to extracellular matrix remodeling, tumor invasion, and angiogenesis, making it an attractive therapeutic target for triple-negative breast cancer (TNBC). The present study aimed to develop non-hydroxamate MMP-9 inhibitors based on a substituted 1,2,3-triazolyl-benzoylacetamide scaffold and evaluate their antiproliferative and anti-angiogenic potentials. An energy-based, structure-guided pharmacophore approach was employed to define the key recognition features of the MMP-9 catalytic domain, including the catalytic Zn²⁺ environment and S1′ specificity pocket. A focused series of 13 derivatives (8a–8m) was subsequently designed through systematic modification of the benzoyl R¹ and terminal phenoxy R² regions, synthesized through a multistep route, and structurally characterized using spectroscopic and mass-spectrometric methods. The synthesized compounds exhibited concentrationdependent MMP-9 inhibition and antiproliferative activity against MDA-MB-231 cells, with the SAR analysis demonstrating a strong dependence on the combined steric, electronic, and lipophilic characteristics of R¹ and R². Compound 8h emerged as the principal lead, whereas 8e and 8l also displayed favorable biochemical and cellular activity profiles. Morphological evaluation further supported the cellular effects of these active derivatives. Functional antiangiogenic assessment demonstrated that 8h concentration-dependently suppressed VEGF-induced HUVEC migration and disrupted capillary-like tube formation, approaching the activity of the reference anti-angiogenic agent at higher tested concentrations. Collectively, these findings identify substituted 1,2,3-triazolyl-benzoylacetamides as a promising nonhydroxamate chemotype for MMP-9-directed anti-angiogenic drug discovery and establish 8h as a lead candidate for further mechanistic, selectivity, pharmacokinetic, and in vivo evaluations.
Authors
- Shaik Khasimbi (ORCID: https://orcid.org/0000-0002-8238-249X)
- Sharad Wakode
Institutions
- Delhi Pharmaceutical Science and Research University (IN)
Publication Details
- Journal
- International Journal of Drug Delivery Technology
- Published
- 2026-11-16
- DOI
- https://doi.org/10.25258/ijddt.16.80s.45
- Primary Topic
- Protease and Inhibitor Mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 0.00